Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: Results from the double-blind placebo-controlled MASCOT study

Annals of the Rheumatic Diseases

Volumn 66, Issue 2, 2007, Pages 235-241

  Capell, Hilary A ^a   Madhok, Rajan ^a   Porter, Duncan R ^b   Munro, Robin A L ^c   McInnes, Iain B ^a   Hunter, John A ^c   Steven, Malcolm ^d   Zoma, Asad ^e   Morrison, Elaine ^f   Sambrook, Martin ^a   Fat, Wui Poon ^a   Hampson, Rosemary ^a   McDonald, Fiona ^a   Tierney, Ann ^a   Henderson, Neil ^g   Ford, Ian ^g  

^a GLASGOW ROYAL INFIRMARY   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c WISHAW GENERAL HOSPITAL   (United Kingdom)

^d RAIGMORE HOSPITAL   (United Kingdom)

^e HAIRMYRES HOSPITAL   (United Kingdom)

^f SOUTHERN GENERAL HOSPITAL   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; FOLIC ACID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROCHLORPERAZINE; SULFALAZINE;

ADULT; AGED; ARTICLE; CELLULITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE ACTIVITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FEVER; GINGIVA BLEEDING; HEADACHE; HEMATURIA; HUMAN; LEUKOCYTE COUNT; LIVER FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MOUTH ULCER; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; PRURITUS; RASH; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT RESPONSE; X RAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; SCOTLAND; SULFASALAZINE; TREATMENT OUTCOME;

EID: 33846864259     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2006.057133     Document Type: Article

References (35)

1. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts. Arthritis Rheum 2001;44:1234-6.
2. O'Dell JR. Treating rheumatoid arthritis early: a window of opportunity? Arthritis Rheum 2002;46:283-5.
3. SIGN Guidelines number 48. Management of early RA, December, 2000.
4. Haagsma CJ, van Reil PLCM, de Rooij DJRA, Vree TB, Russel FJM, van't Hof MA, et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: a randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol 1994;33:1049-55.
5. Haagsma CJ, van Rief PLCM, de Jong AJL, van de Putte LBA. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomised, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1982-8.
6. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220-5.
7. Dougados M, Emery P, Lemmel EM, Zerbini CAF, Brin S, van Riel P. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide? Ann Rheum Dis 2005;64:44-51.
8. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
9. Möttönen T, Hannonen P, Leriisalo-Repo M, Nissila M, Kautiainen H, Lorpela M, et al. Comparison of combination therapy with single-dose drug therapy in early rheumatoid arthritis: a randomised trial. Lancet 1999;353:1568-73.
10. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexote alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
11. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine or a combination of the three medications: results of a two year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
12. Boers M, Verhoeven AC, Markusse HM, van de Laar MAFJ, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
13. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med 1995;333:137-41.
14. Felsen DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. Arthritis Rheum 1994;37:1487-91.
15. Verhoeven A, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. Br J Rheum 1998;37:612-19.
16. Smolen J, Aletarn D, Keystone E. Superior efficacy of combination therapy in rheumatoid arthritis: fact or fiction? Arthritis Rheum 2005;52:2975-83.
17. Landewe RBM, Boers M, Verhoeven AC, Westhovens R, van de Laar MAFJ, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis. Arthritis Rheum 2002;46:347-56.
18. Goekoop Ruiterman Y, de Vries-Bouwstan J, Allant C, van Zeber D, Kersters P, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies people with early RA (the BeSt study). A randomised controlled trial. Arthritis Rheum 2005;52:3381-90.
19. Furst DE, Breedveld FC, Kalden JR, Smolen JS, Burmester GR, Bijlsma JWJ, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor α (TNFα) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases. Ann Rheum Dis 2005;64:iv2-14.
20. National Institute for Clinical Excellence. Guidance on the use of etanercept and infliximab for the treatment of rheumatoid arthritis: technology appraisal guidance no. 36. London: National Clinical Institute, 2002:7.
21. Symmons DPM. Anti-tumour necrosis factor α therapy: can we afford it? Ann Rheum Dis 2005;64:969-70.
22. Askling J, Fored CM, Baecklund E, Brandt L, Backlin C, Ekbon A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-20.
23. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1421-6.
24. Winthrop KL. Update on tuberculosis and other opportunistic infections associated with drugs blocking tumour necrosis factor α. Ann Rheum Dis 2005;64:iv29-30.
25. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85.
26. British National Formulary. 4 Mar 2006.
27. van der Heijde DMFM, van't Hof MA, van Riel PLCM, Theunisse LAM, Lubberts EW, van Leeuwen MA, et al. Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score. Ann Rheum Dis 1990;49:916-20.
28. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MD, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Arth Rheum 1996;39:34-40.
29. Treasure T, MacRae KD. Minimisation: the platinum standard for trials? Randomisation doesn't guarantee similarity of groups: minimisation does [editorial], Br Med J 1998;317:362-3.
30. Felsen DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definitions of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727- 35.
31. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 1999;26:743-5.
32. Porter DR, Capell HA, Hunter J. Combination therapy in rheumatoid arthritis - no benefit of addition of hydroxychloroquine to patients with a suboptimal response to intramuscular gold therapy. J Rheumatol 1993;20:645-9.
33. Fransen J, van Riel PLCM. The disease activity score and the EULAR response criteria. Clin Exp Rheumatol 2005;23(Suppl 39):S93-9.
34. Jansen G, van der Heijden J, Oerlemans R, Lems WF, Ifergan I, Scheper RJ, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier. Arthritis Rheum 2004;50:2130-9.
35. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. American College of Rheumatology European League of Association for Rheumatology. J Rheumatol 1999;26:705-11.